APPLICATION OF CYCLODEXTRIN IN NDDS

Views:
 
     
 

Presentation Description

No description available.

Comments

By: chakri.neerukonda (37 month(s) ago)

it is not an open plz open it ppt

Presentation Transcript

ndds: application of cyclodextrin : 

ndds: application of cyclodextrin Presented by: Nikhil Jogad Scientist 1

CONTENTS : 

CONTENTS INTRODUCTION PROFILE RATIONALE USES IN NDDS 2

INTRODUCTION : 

INTRODUCTION CYCLODEXTRIN IS A WELL ACCEPTED POLYMER IN PHARMACEUTICAL FORMULATIONS. IT IS A POLYMER WITH A LOT OF SOLUTIONS FOR DRUG SOLUBILITY. IT IS A POLYMER BOON FOR F & D. 3

PROFILE : 

PROFILE NAME : CYCLODEXTRIN SYNONYM:CAVITRON,CYCLOAMYLOSE,CYCLOGLUCAN,CYCLICOLIGOSACCHARIDE MOLECULAR WEIGHT:1135 M.P. : 255-2650C 4

TYPES : 

TYPES 5

Slide 6: 

STRUCTURAL FORMULA: β CYCLODEXTRIN 6

CAVITY DIMENSIONS : 

CAVITY DIMENSIONS 7

RATIONALE : 

RATIONALE INCREASE SOLUBILITY OF HYDROPHOBIC DRUGS. INCREASE HEAT RESISTANCE TO DRUGS. INCREASE OXIDATION RESISTANCE TO DRUGS. INCREASE HYDROLYSIS RESISTANCE TO DRUGS. INCREASE BIOAVAILABILITY OF DRUG. DECREASE GASTROINTESTINAL IRRITATION BY DRUGS. DECREASE ENZYMATIC DEGRADATION OF DRUG. 8

APPLICATION TO NDDS : 

APPLICATION TO NDDS 9

COMPLEXATION -MECHANISM : 

COMPLEXATION -MECHANISM HYDROPHILIC GROUP:-OH HYDROPHOBIC GROUP:-COOH 10

COMPLEX FORMED : 

COMPLEX FORMED TWO TYPE OF COMPLEX: TYPE-A(L) :IT FORMS IN SOLUTIONS. TYPE-B(S) : IT FORMS IN SOLIDS. 11 DIAGRAM:

TDDS : 

TDDS Gel prepared by incorporating glipizide-beta-CyD complex in Carbopol gel base in presence of 15% urea. The glucose tolerance test showed suppression of hyperglycaemia. 12

CONTROLLED RELEASE : 

CONTROLLED RELEASE MELOXICAM- β CD-COMPLEX IN 1:2 RATIO 13

SUSTAINED RELEASE : 

SUSTAINED RELEASE CAPTOPRIL (ACE -INHIBITOR) Decrease in hydrolysis. 14

OPTHALMIC : 

OPTHALMIC DECREASED OXIDATION OF PILOCARPIN EYE DROPS 15

INTRAVAGINAL : 

INTRAVAGINAL CLOTRIMAZOL: VAGINITIS TREATMENT. 1:4 CMPLEX IS REQUIRED FOR BEST SOLUBILIZATION. 16

COMPLEXATION METHODES : 

COMPLEXATION METHODES KNEADING PULVERISATION EVAPORATION FREEZING POINT DEPRESSION 17

EVALUATION METHODES : 

EVALUATION METHODES FLUORESCENCE STUDY UV SPECTROSCOPY VAPOUR PRESSURE OSMOMETRY MODIFIED COLORIMETRY IN SITU RAT GUT DISSOLUTION THERMOMETRIC: DSC ,DTG, DTA. 18

FUTURE TREND : 

FUTURE TREND Inhalation:Budesonide nebulizer. Oral Liquid :anti-arthritis :Fexofenadine. Parenteral :Amiodaron, Propofol. New innovations in wound odor control. 19

REFERENCES : 

REFERENCES VARMA MOHAN,SHANKAR K R CYCLODEXTRIN:NOVEL EXCIPIENTS FOR ENHANCING THE STABILITY OF POORLY STABLE DRUGS. JOURNAL OF PHARMACEUTICAL SCIENCES(2005):4:1:6-8 IKEDA Y,SOHKO MINCLUSION COMPLEX FORMATION OF CAPTOPRIL WITH CYCLODEXTRIN IN AQUEOUS SOLUTION. JOURNAL OF PHARMACEUTICAL SCIENCES(2005):91:11:2390 RAWAT S,JAIN SK CHARACTERIZATION OF THE INCLUSION COMPLEX OF MELOXICAM AND β CYCLODEXTRIN TO ENHANCE THE DISSOLUTION AND BIOAVAILABILITY.INTERNATIONAL JOURNAL OF PHARMACEUTICAL EXCIPIENTS(2005):4:4:112-115 20

Slide 21: 

MAITANIY,KOWANOK CURRENTPHARMACEUTICALBIOTECHNOLOGY: 2005:6:81-83 AMMAR H O,SALAMA H A CURRENT DRUG DELIVERY:2006:3:333-341 JOURNAL OF INCLUSION PHENOMENON AND MACROCYCLIC CHEMISTRY:2006:56:3-8 MOSHER G,THOMPSON D COMPLEXATION AND CYCLODEXTRIN ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY :2:1:531-558 HANDBOOK OF PHARMACEUTICAL EXCIPIENTS:RAYMOND C,WELLER:4:186-189 21

Slide 22: 

THE SCIENCE AND PRACTICE PHARMACY:20:1:190-191 PHARMACEUTICAL EXCIPIENT CHARACTERISATION:BUGAS D,FINDALE W:94:181 ADVANCES IN CONTROLLED AND NOVEL DRUG DELIVERY:JAIN N:1:40 TARGETED AND CONTROLLED DRUG DELIVERY:NOVEL CARRIER SYSTEM:VYAS S,KHAR R:1:23-24 COATED PHARMACEUTICAL DOSAGE FORM:BAUR,LEHMANN,OSTERWALD,ROTHGANG:123 22

Slide 23: 

23 THANK YOU